Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- NRS pain scores
研究概览
简要总结
This study seeks to evaluate the use of intermittent dosing as an alternative paradigm for patients with DRG stimulation in place for at least 1 year and minimum 50% pain relief in the targeted area.
Patients will be prospectively randomized to one of two stimulation paradigms both of which involve intermittent dosing at 30 seconds ON and 90 seconds OFF. Group 1 will have their frequency set at 20 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation). Group 2 will have their frequency set at 5 Hz with amplitude levels adjusted in order to remain in the therapeutic window (subthreshold stimulation) This study will be performed in a crossover fashion, meaning patients will be changed to the alternate dosing regimen at the 13-week time period.
Patients will be seen and evaluated prior to randomization and reprogramming, and thereafter evaluated at 4, 8, and 12-weeks. At the 12-week time period, patients will begin a 1-week washout period of continuous stimulation. At the 13-week time period, patients will be evaluated, crossed over to the other study arm and thereafter evaluated at 17, 21, and 25-weeks.
详细描述
Dorsal Root Ganglion (DRG) is a novel target of neuromodulation that's use has grown as a proven effective treatment in chronic painful conditions. Studies examining tonic, paresthesia-based dorsal column stimulation have demonstrated plateauing or diminishing effects after extended time periods. Although not yet studied in DRG stimulation due to its relative infancy, the possibility of decreased pain relief over time very much exists. In order to mitigate the potential for waning pain relief over time, other paradigms of stimulation within the framework of DRG therapy must be evaluated.
Intermittent dosing (ID) refers to the cycling of stimulation, in which there is a designated time period of stimulation being active (ON) and inactive (OFF). Previous studies have demonstrated the safe and effective use of intermittent dosing using spinal cord stimulation (SCS).9,10 In 2020, Deer et al. reported the efficacy of intermittent dosing of Burst stimulation with settings ranging from 30 seconds ON and 90 seconds OFF, to 30 seconds ON and 360 seconds OFF in SCS.10 However, no studies have examined the use of ID in DRG stimulation. Furthermore, a pre-clinical study by Chao et al. 2020 showed that DRG field stimulation delivered at 20 Hz continuously abated transmission of action potentials in most C-type fibers and 50% of Aδ fibers. Conversely, DRG field stimulation delivered at 5 Hz consistently evoked action potentials in Aβ, Aδ, and C type fibers, suggesting that this frequency may have greater potential to mitigate pain11. Nevertheless, translation of these results to clinical practice have yet to be studied.
Patients with chronic pain secondary to CRPS or other chronic neuropathic who have responded to DRG stimulation originally and have undergone permanent DRG stimulator implantation delivered by the Abbott PROCLAIM Dorsal Root Ganglion Neurostimulator System, have had the system in place for at least 1 year, utilizing continuous tonic therapy, reporting minimum 50% pain relief in the targeted area, will be randomized to 1 of 2 study arms, in a single-blinded, 1:1 fashion:
- High ID Arm: DRG stimulation therapy at 20 Hz frequency for 30 seconds ON, 90 seconds OFF
- Low ID Arm: DRG stimulation therapy at 5 Hz frequency for 30 seconds ON, 90 seconds OFF
Based on the stimulation frequency each patient receives the stimulation amplitude will be adjusted accordingly to remain in the therapeutic dosing window for each patient.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
盲法说明
Participants will not know to which treatment they are randomized
入排标准
- 年龄范围
- 18 Years 至 90 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 99
- •1-year or more use of continuous DRG therapy as delivered a permanently implanted Abbott PROCLAIM XR Dorsal Root Ganglion Neurostimulator System for chronic back and/or leg pain
- •Endorse at least 50% pain relief in the targeted area over the last year
- •Must have been seen for routine follow-up within last 4 months
- •Must have been reprogrammed in standard fashion at least once prior to randomization
- •Willing and able to complete protocol requirements, including:
- •Complete health questionnaires and pain scales as specified in the protocol
- •Sign the study-specific informed consent form
- •Complete follow-ups at the designated time periods
排除标准
- •Significant lead migration, as determined by clinician
- •Other concurrent neuromodulation system in place
- •Corticosteroid injection in previous 30 days prior to enrollment
- •Intermittent dosing and/or failure within last 6m
- •Changing or unstable pain medications within 30 days
结局指标
主要结局
NRS pain scores
时间窗: Up to 6 months
Subject's Numeric Rating Scale (NRS) score for pain being treated by DRG simulation for up to 3 months of designated treatment on a 22 point scale from 0-10 in 0.5 increments with 0 being no pain to 10 being the worse imaginable pain.
次要结局
- Charging frequency of DRG stimulator(Up to 6 months)
- PROMIS- Fatigue 8 questionnaire(Up to 6 months)
- Patient Satisfaction with Treatment Score(Up to 6 months)
- CPAQ-8(Up to 6 months)
- Current mode of stimulation(Up to 6 months)
- Stimulator settings- frequency(Up to 6 months)
- Stimulator settings- amplitude(Up to 6 months)
- Stimulator settings- pulse width(Up to 6 months)
- PROMIS- Global Health 10 item questionnaire(Up to 6 months)
- PROMIS- Sleep Disturbance 4a questionnaire(Up to 6 months)
- PROMIS- Emotional Distress- 8a Anxiety questionnaire(Up to 6 months)
- PROMIS- Physical Function 8b questionnaire(Up to 6 months)
- PROMIS- Pain Interference 6b questionnaire(Up to 6 months)
- PHQ-8(Up to 6 months)
- Patient Global Impression of Change(Up to 6 months)
研究者
Sandeep Amin, MD
Principal Investigator- Anesthesia Department (Provider)
Rush University Medical Center
